05/22/2002 By Elda Hauschildt
Lower doses of estrogens and estrogens with medroxyprogesterone acetate (MPA) effectively increase bone mineral density (BMD) and bone mineral content (BMC) for women in the early years after menopause.
Data from a sub-study of the Women’s Health, Osteoporosis, Progestin, Estrogen (Women’s HOPE) trial in the United States indicate that lower doses of conjugated equine estrogens (CEEs), with or without a lower dose of MPA, prevent loss of spine and hip BMD and reduce bone turnover.
Researchers define lower doses of CEEs as 0.45 and 0.3 milligrams per day and lower doses of MPA are defined as 1.5 mg/d.
“Using lower doses of both estrogens and progestins makes clinical sense and may enhance compliance with and initiation of therapy by enhancing the benefit-risk ratio,” they say. Women’s Hope was conducted at 19 US centres between August 1995 and October 2000. It demonstrated the beneficial effects of low-dose CEEs-MPA regimens on vasomotor symptoms and vaginal atrophy, lipid profiles, bleeding profiles and endometrial hyperplasia. Eight hundred and twenty two participants, aged 40 to 65 years, participated in the two-year, double-blinded placebo-controlled Women’s HOPE sub-study. They were within four years of their last menstrual cycle.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!